Business & Tech
    Next Score View the next score

    FDA approves Sarepta’s controversial drug for Duchenne muscular dystrophy

    The Food and Drug Administration on Monday approved a controversial drug to treat Duchenne muscular dystrophy, a rare disease that confines boys to wheelchairs and sends them to an early grave.

    The decision came after a protracted debate about whether drug maker Sarepta Therapeutics had provided enough evidence that its medication, called eteplirsen, had meaningful impact on patients.

    The approval delighted a frazzled, but vociferous community of parents, whose determined lobbying efforts were reminiscent of the movement three decades ago to force regulators to greenlight AIDS treatments. And the FDA endorsement also jazzed investors, who sent Sarepta shares soaring, while breathing new life into still other companies that are investigating Duchenne treatments.

    Advertisement

    The fate of the Sarepta drug has been closely watched as a litmus test for an intensifying struggle between the FDA and patient groups that want the agency to take a more expansive view toward approving medicines for unmet medical needs. In this instance, patient advocates hoped the FDA would use the accelerated approval process to endorse eteplirsen. This approach relies on a substitute outcome in a clinical trial to suggest a drug may have, but does not guarantee, a benefit.

    Get Talking Points in your inbox:
    An afternoon recap of the day’s most important business news, delivered weekdays.
    Thank you for signing up! Sign up for more newsletters here

    It was a long and complicated road, however, to this moment, as the FDA and Sarepta squabbled repeatedly over several technical, but significant details.

    A key issue was whether the drug can sufficiently produce higher levels of a protein called dystrophin. Without this protein, muscle fibers degenerate and voluntary movement becomes impossible. The FDA also raised doubts about the results of a small, 12-patient clinical trial that Sarepta relied on to make its case, as well as the viability of six-minute walking tests that trial participants underwent. Moreover, the company failed to conduct a larger trial involving the use of a placebo, as the FDA had requested.

    In light of these concerns, an FDA advisory panel in April voted that the drug should not be approved and, by a narrow margin, also agreed that the drug does not appear to be effective. Their recommendations were made at a day-long meeting that was punctuated by a parade of emotional pleas from parents and children, some of whom appeared in wheelchairs.

    Despite the outcome, the agency appeared to signal that parents should not lose hope. In remarks designed to appease the crowd, Janet Woodcock, who heads the agency division that approves drugs, said that “It’s possible to reach different conclusions based on the data presented today… Failing to approve a drug that actually works in devastating diseases — these consequences are extreme.”

    Advertisement

    And so, the FDA made an unexpected request for Sarepta to provide more data about muscle biopsies from 13 boys who participated in an ongoing trial in order to determine the extent to which the medicine may produce dystrophin. The move suggested that the FDA tried to find other ways to approve the drugs, although some believed the agency was attempting to lay the groundwork to argue that they had left no stone unturned before issuing a rejection.

    Ed Silverman can be reached at ed.silverman@statnews.com. Follow Ed on Twitter @Pharmalot